STAT· @statnews · X·· 1 小时前精选AI 评分62
AI 导读
礼来一项在研复方疗法在中期研究中带来显著减重，但受试者停药比例较高，可能引发对其耐受性的疑问。相关研究结果由STAT News报道，链接为 https://www.statnews.com/2026/09/30/eli-lilly-zepbound-amylin-combination-drug-study/。
推荐理由
礼来在研复方减重疗法中期研究显示显著减重，但停药率偏高，读者可据此关注其耐受性风险。
正文
An investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high rates of people stopping the treatment may raise questions about its tolerability. https://www.statnews.com/2026/09/30/eli-lilly-zepbound-amylin-combination-drug-study/
来源：STAT · x.com